Ying Luo Biography and Net Worth

Dr. Luo received his doctorate in molecular biology/biomedical sciences from the University of Connecticut Health Center in 1991. He later studied HIV gene regulation in UCSF as a postdoctoral fellow. Prior to founding Shanghai Genomics in 2001, Dr. Luo held various positions at the San Francisco Bay Area biotech firms, including Aviron, Clonetech, and Rigel. Later Shanghai Genomics was acquired by GNI Group and became listed on the Tokyo Stock Exchange Mothers Board in 2007. He is currently President and CEO of GNI Group. The pre-clinical, clinical, and regulatory teams recruited and supervised by him has successfully gained 6 IND approvals and conduct Phase I/II trials in China or US. Under his leadership, GNI Group had its first Class 1 drug Etuary® approved by China FDA in treating IPF in 2011 through expedited review process. Later he built a nationwide orphan drug sales network in China. Recently, he also engineered several acquistions for GNI, including Beijing Continent and Berkeley Advanced Biomaterials, and investments into other joint ventures. In his career of 30 years, Dr. Luo has co-authored more than 35 research publications and been inventors of more than 16 patents.